Emma Walmsley, GSK CEO
GSK bullish on RSV vaccine battle against Pfizer, ships first Arexvy dose
GSK is bullish about the market prospects for its RSV vaccine Arexvy in older adults.
The Big Pharma has already shipped its first doses to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
